{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:40:28Z","timestamp":1766407228017,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clml.2022.11.001","type":"journal-article","created":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T01:20:58Z","timestamp":1667697658000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data"],"prefix":"10.1016","volume":"23","author":[{"given":"Vladimir","family":"Maisnar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-326X","authenticated-orcid":false,"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Jungova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7072-8537","authenticated-orcid":false,"given":"Martin","family":"Stork","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Straub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Radocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Pika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-5364","authenticated-orcid":false,"given":"Peter","family":"Kunovszki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.11.001_bib0001","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.11.001_bib0002","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.11.001_bib0003","unstructured":"Cancer facts and figures, 2017. Accessed on May 5, 2017. Available at: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2017\/cancer-facts-and-figures-2017.pdf"},{"key":"10.1016\/j.clml.2022.11.001_bib0004","unstructured":"European Commission, European Cancer Information System. Accessed and data filtered on September 4, 2021 Available at: https:\/\/ecis.jrc.ec.europa.eu\/index.php"},{"key":"10.1016\/j.clml.2022.11.001_bib0005","doi-asserted-by":"crossref","unstructured":"Maluskova D, Svobodov\u00e1 I, Kucerova M, et\u00a0al. Epidemiology of multiple myeloma in the Czech Republic. Klin Onkol;30(Supplementum2):35-42. English. doi: 10.14735\/amko20172S35. PMID: 28903569.","DOI":"10.14735\/amko20172S35"},{"key":"10.1016\/j.clml.2022.11.001_bib0006","unstructured":"Cancer Stat Facts: Myeloma. Accessed on May 5, 2017. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"10.1016\/j.clml.2022.11.001_bib0007","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.001_bib0008","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.001_bib0009","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.001_bib0010","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.001_bib0011","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2022.11.001_bib0012","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.001_bib0013","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.001_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.11.001_bib0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/hon.2949","article-title":"Salvage therapy with \u201cDara-KDT-P(A)CE\u201d in heavily pretreated, high-risk, proliferative, relapsed\/refractory multiple myeloma","volume":"40","author":"Zhou","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.11.001_bib0016","article-title":"Real-world outcome in the pre-car-T era of myeloma patients qualifying for Car-T cell therapy: real-world assessment of myeloma patients as candidates for CAR-T therapy","volume":"13","author":"Bacher","year":"2021","journal-title":"Mediterranean J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2022.11.001_bib0017","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.11.001_bib0018","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood-2021-146250","article-title":"Real-world outcomes for standard-of-care treatments in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Delforge","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.001_bib0019","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.3390\/cancers13235996","article-title":"Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, Imid and anti-CD-38 from a German registry","volume":"13","author":"Merz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2022.11.001_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","article-title":"Comparative efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma","volume":"42","author":"Weisel","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clml.2022.11.001_bib0021","article-title":"Comparison of Cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","author":"Costa","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.11.001_bib0022","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or double refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2022.11.001_bib0023","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.24781","article-title":"Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: an adjusted treatment comparison","volume":"92","author":"Usmani","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.11.001_bib0024","unstructured":"Bratulic A. BMS, bluebird's CAR-T Abecma wins FDA approval for multiple myeloma. Accessed on July 15, 2022. Available at: https:\/\/new.firstwordpharma.com\/story\/5259579"},{"key":"10.1016\/j.clml.2022.11.001_bib0025","unstructured":"Bristol Myers Squibb Canada Co. Health Canada Approves ABECMA (idecabtagene vicleucel), the First and Only Anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma. Accessed on July 15, 2022. Available at: https:\/\/new.firstwordpharma.com\/story\/5313919"},{"key":"10.1016\/j.clml.2022.11.001_bib0026","unstructured":"Bratulic A. BMS wins EU approval for CAR-T therapy Abecma to treat multiple myeloma. Accessed on July 15, 2022. Available at: https:\/\/new.firstwordpharma.com\/story\/5379275"},{"key":"10.1016\/j.clml.2022.11.001_bib0027","unstructured":"Bratulic A. FDA approves J&J, Legend's CAR-T therapy Carvykti. Accessed on July 15, 2022. Available at: https:\/\/firstwordpharma.com\/story\/5514997"},{"key":"10.1016\/j.clml.2022.11.001_bib0028","unstructured":"Bratulic A. CAR-T therapies Carvykti, Kymriah lead latest batch of CHMP nods. Accessed on July 15, 2022. Available at: https:\/\/firstwordpharma.com\/story\/5533481"},{"issue":"Supplementum2","key":"10.1016\/j.clml.2022.11.001_bib0029","first-page":"43","article-title":"Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation","volume":"30","author":"Brozova","year":"2017","journal-title":"Klin Onkol"},{"key":"10.1016\/j.clml.2022.11.001_bib0030","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.001_bib0031","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/fon-2020-1003","article-title":"Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA","volume":"17","author":"Madduri","year":"2021","journal-title":"Future Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:31Z","timestamp":1761871291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2152265022017189"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.11.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}